Galmed Pharmaceuticals analyst ratings
Galmed Pharmaceuticals analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2022 | 120.99% | Canaccord Genuity | $5 → $1 | Downgrades | Buy → Hold |
| 05/18/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 05/03/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/03/2022 | 1004.97% | Raymond James | $14 → $5 | Maintains | Outperform |
| 05/17/2021 | 4540.88% | Canaccord Genuity | $20 → $21 | Maintains | Buy |
| 03/19/2021 | 5424.86% | HC Wainwright & Co. | $29 → $25 | Maintains | Buy |
| 01/08/2021 | 3656.91% | Raymond James | $20 → $17 | Maintains | Outperform |
| 11/25/2020 | 4319.89% | Canaccord Genuity | $25 → $20 | Maintains | Buy |
| 05/22/2020 | 1667.96% | B. Riley Securities | $11 → $8 | Downgrades | Buy → Neutral |
| 05/15/2020 | 4319.89% | Raymond James | $25 → $20 | Maintains | Outperform |
| 03/13/2020 | 5424.86% | Stifel | $35 → $25 | Maintains | Buy |
| 03/13/2020 | 2330.94% | B. Riley Securities | $28 → $11 | Maintains | Buy |
| 02/04/2020 | 3877.9% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 01/30/2020 | 2993.92% | Cantor Fitzgerald | $59 → $14 | Assumes | → Overweight |
| 07/22/2019 | 5424.86% | Laidlaw & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/12/2018 | 6087.85% | B. Riley Securities | → $28 | Initiates Coverage On | → Buy |
| 07/20/2018 | 5645.86% | Raymond James | → $26 | Initiates Coverage On | → Outperform |
| 07/13/2018 | 7634.81% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 07/11/2018 | 12938.67% | Cantor Fitzgerald | → $59 | Initiates Coverage On | → Overweight |
| 06/13/2018 | 6529.83% | Maxim Group | $14 → $30 | Maintains | Buy |
| 03/15/2018 | — | Maxim Group | Upgrades | Hold → Buy | |
| 02/14/2018 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/15/2017 | 6971.82% | Roth Capital | → $32 | Initiates Coverage On | → Buy |
| 10/06/2017 | 4098.9% | Seaport Global | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/08/2022 | 120.99% | 卡納科特·格納奇 | $5 → $1 | 評級下調 | 購買→Hold |
| 05/18/2022 | — | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 05/03/2022 | — | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 05/03/2022 | 1004.97% | 雷蒙德·詹姆斯 | $14 → $5 | 維護 | 跑贏大盤 |
| 05/17/2021 | 4540.88% | 卡納科特·格納奇 | $20 → $21 | 維護 | 買 |
| 03/19/2021 | 5424.86% | HC Wainwright公司 | $29 → $25 | 維護 | 買 |
| 01/08/2021 | 3656.91% | 雷蒙德·詹姆斯 | $20 → $17 | 維護 | 跑贏大盤 |
| 11/25/2020 | 4319.89% | 卡納科特·格納奇 | $25 → $20 | 維護 | 買 |
| 05/22/2020 | 1667.96% | B.萊利證券 | $11 → $8 | 評級下調 | 購買→中性 |
| 05/15/2020 | 4319.89% | 雷蒙德·詹姆斯 | $25 → $20 | 維護 | 跑贏大盤 |
| 03/13/2020 | 5424.86% | Stifel | $35 → $25 | 維護 | 買 |
| 03/13/2020 | 2330.94% | B.萊利證券 | $28 → $11 | 維護 | 買 |
| 02/04/2020 | 3877.9% | 克雷格-哈勒姆 | → $18 | 開始承保 | →購買 |
| 01/30/2020 | 2993.92% | 康託·菲茨傑拉德 | $59 → $14 | 假設 | →超重 |
| 07/22/2019 | 5424.86% | 萊德勞公司 | → $25 | 開始承保 | →購買 |
| 12/12/2018 | 6087.85% | B.萊利證券 | → $28 | 開始承保 | →購買 |
| 07/20/2018 | 5645.86% | 雷蒙德·詹姆斯 | → $26 | 開始承保 | →跑贏大盤 |
| 07/13/2018 | 7634.81% | Stifel | → $35 | 開始承保 | →購買 |
| 07/11/2018 | 12938.67% | 康託·菲茨傑拉德 | → $59 | 開始承保 | →超重 |
| 06/13/2018 | 6529.83% | Maxim集團 | $14 → $30 | 維護 | 買 |
| 03/15/2018 | — | Maxim集團 | 升級 | 持有→購買 | |
| 02/14/2018 | — | Maxim集團 | 評級下調 | 購買→Hold | |
| 11/15/2017 | 6971.82% | 羅斯資本 | → $32 | 開始承保 | →購買 |
| 10/06/2017 | 4098.9% | 環球海港 | → $19 | 開始承保 | →購買 |
Galmed Pharmaceuticals Questions & Answers
Galmed PharmPharmticals問答
The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Canaccord Genuity on August 8, 2022. The analyst firm set a price target for $1.00 expecting GLMD to rise to within 12 months (a possible 120.99% upside). 4 analyst firms have reported ratings in the last year.
加萊德製藥公司(納斯達克代碼：GLMD)的最新目標價是由Canaccel Genuity於2022年8月8日報道的。這家分析公司將目標價定為1美元，預計GLMD將在12個月內升至(可能上漲120.99%)。去年有4家分析公司公佈了評級。
The latest analyst rating for Galmed Pharmaceuticals (NASDAQ: GLMD) was provided by Canaccord Genuity, and Galmed Pharmaceuticals downgraded their hold rating.
Galmed製藥公司(納斯達克代碼：GLMD)的最新分析師評級由Canaccel Genuity提供，Galmed製藥公司下調了其持有評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on August 8, 2022 so you should expect the next rating to be made available sometime around August 8, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Galmed製藥的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Galmed製藥的上一次評級是在2022年8月8日提交的，所以你應該預計下一次評級將在2023年8月8日左右提供。
While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a downgraded with a price target of $5.00 to $1.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $0.45, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Galmed PharmPharmticals(GLMD)的最新評級被下調，目標價為5.00美元至1.00美元。Galmed PharmPharmticals(GLMD)目前的股價為0.45美元，超出了分析師的預測區間。